Nektar Therapeutics (NKTR) News Today $0.67 +0.02 (+3.12%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.67 0.00 (-0.67%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NKTR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Nektar Therapeutics Elects New Board, Approves Key ProposalsMay 28 at 6:34 AM | tipranks.comNektar Therapeutics (NASDAQ:NKTR) Position Boosted by Woodline Partners LPWoodline Partners LP lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 187.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,974,512 shares of the biopharmaceutical company's stock after purMay 26 at 4:44 AM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Buy" by BrokeragesMay 26 at 4:07 AM | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $15,549.36 in StockMay 22, 2025 | insidertrades.comNektar at H.C. Wainwright: Respag’s Promising FutureMay 21, 2025 | investing.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Buy" from BrokeragesShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have received an average recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendMay 21, 2025 | marketbeat.comShay Capital LLC Sells 1,243,072 Shares of Nektar Therapeutics (NASDAQ:NKTR)Shay Capital LLC lessened its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 77.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 352,204 shares of the biopharmaceutical company's stock after selling 1,243,072 shares during the periMay 19, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Nektar Therapeutics (NASDAQ:NKTR)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,580,916 shares of the biopharmaceutical coMay 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for NKTR Q2 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued on Monday, May 12th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company willMay 16, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 15, 2025 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Given "Market Perform" Rating at William BlairWilliam Blair restated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday.May 14, 2025 | marketbeat.comTime To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) OutlookMay 13, 2025 | finance.yahoo.comNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 13, 2025 | prnewswire.comAnticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar TherapeuticsMay 12, 2025 | tipranks.comEarnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progressMay 10, 2025 | uk.investing.comQ1 EPS Estimates for Nektar Therapeutics Lowered by B. RileyNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at B. Riley reduced their Q1 2025 earnings estimates for Nektar Therapeutics in a research report issued on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($0.May 10, 2025 | marketbeat.comNektar Therapeutics's Earnings: A PreviewMay 9, 2025 | nasdaq.comNektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025May 9, 2025 | msn.comDeep Track Capital LP Reduces Stock Position in Nektar Therapeutics (NASDAQ:NKTR)Deep Track Capital LP trimmed its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 87.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,975,998 shares of the biopharmaceutical compaMay 9, 2025 | marketbeat.comNektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...May 9, 2025 | gurufocus.comNektar Therapeutics (NKTR) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock NewsMay 8, 2025 | gurufocus.comNektar Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | prnewswire.com4NKTR : Nektar Therapeutics's Earnings: A PreviewMay 7, 2025 | benzinga.comNektar TherapeuticsMay 6, 2025 | marketwatch.com22Nw LP Takes Position in Nektar Therapeutics (NASDAQ:NKTR)22Nw LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,191,750 shares of the biopharmaceutical company's stock, valued at approximately $2,038,000. Nektar Therapeutics makes upMay 4, 2025 | marketbeat.comNektar Therapeutics (NKTR) to Release Earnings on ThursdayNektar Therapeutics (NASDAQ:NKTR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-nektar-therapeutics-stock/)May 3, 2025 | marketbeat.comNektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial MarketsMay 1, 2025 | prnewswire.comNantahala Capital Management LLC Acquires 3,700,000 Shares of Nektar Therapeutics (NASDAQ:NKTR)Nantahala Capital Management LLC increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 90.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,810,000 shares of the biopharmaceuticalApril 30, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Buy" from AnalystsShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have been given an average rating of "Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buyApril 26, 2025 | marketbeat.comRenaissance Technologies LLC Raises Stock Position in Nektar Therapeutics (NASDAQ:NKTR)Renaissance Technologies LLC grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 17.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,910,786 shares of the biopharmaceutical company'sApril 25, 2025 | marketbeat.comDiadema Partners LP Acquires New Holdings in Nektar Therapeutics (NASDAQ:NKTR)Diadema Partners LP purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 698,919 shares of the biopharmaceutical company's stock, valued at apprApril 24, 2025 | marketbeat.comAltium Capital Management LLC Raises Holdings in Nektar Therapeutics (NASDAQ:NKTR)Altium Capital Management LLC raised its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 26,172.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,000,000 shares of the biopharmaceutical company's stock after purchasingApril 20, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at StockNews.comStockNews.com initiated coverage on Nektar Therapeutics in a research note on Wednesday. They issued a "hold" rating on the stock.April 17, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Jefferies Financial GroupJefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $1.00 to $2.00 in a report on Friday.April 13, 2025 | marketbeat.comNektar management to meet virtually with B. RileyApril 12, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Shares Surge on Jefferies UpgradeApril 12, 2025 | gurufocus.comNektar upgraded to Buy from Hold at JefferiesApril 11, 2025 | markets.businessinsider.comJefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00April 11, 2025 | gurufocus.comNektar Therapeutics (NKTR) Gains After Jefferies UpgradeApril 11, 2025 | gurufocus.comNektar Therapeutics stock hits 52-week low at $0.44April 9, 2025 | investing.comEquities Analysts Set Expectations for NKTR Q1 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings perApril 8, 2025 | marketbeat.comQ1 Earnings Estimate for NKTR Issued By Zacks ResearchNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das forecastsApril 6, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Nektar Therapeutics (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 2,351 call options on the stock. This represents an increase of approximately 245% compared to the typical volume of 681 call options.March 29, 2025 | marketbeat.comNektar files $300M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comNektar Therapeutics files $300M mixed securities shelfMarch 28, 2025 | seekingalpha.comNektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf OfferingMarch 28, 2025 | gurufocus.comPiper Sandler Remains a Buy on Nektar Therapeutics (NKTR)March 26, 2025 | markets.businessinsider.comNektar management to meet with Piper SandlerMarch 24, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market TurmoilMarch 22, 2025 | insidermonkey.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.481.03▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼84▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NKTR Stock Free NKTR Stock Alerts